PISANÒ, CLARISSA ANNA
 Distribuzione geografica
Continente #
NA - Nord America 545
EU - Europa 147
AS - Asia 122
OC - Oceania 3
Totale 817
Nazione #
US - Stati Uniti d'America 540
IT - Italia 58
SG - Singapore 47
CN - Cina 45
AT - Austria 32
ID - Indonesia 18
GB - Regno Unito 13
PL - Polonia 10
SE - Svezia 9
DE - Germania 7
BE - Belgio 5
CA - Canada 5
UA - Ucraina 5
AU - Australia 3
TR - Turchia 3
VN - Vietnam 3
FI - Finlandia 2
FR - Francia 2
TW - Taiwan 2
CH - Svizzera 1
ES - Italia 1
HK - Hong Kong 1
IE - Irlanda 1
IN - India 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
Totale 817
Città #
Fairfield 71
Chandler 70
Santa Clara 52
Ashburn 49
Singapore 43
Woodbridge 35
Vienna 32
Ann Arbor 28
Houston 27
Wilmington 27
Seattle 25
Cambridge 24
Jakarta 18
Beijing 17
Ferrara 13
Princeton 13
Shanghai 11
Warsaw 10
Jacksonville 9
Milan 8
Morciano Di Romagna 7
Boardman 5
Brussels 5
Nanjing 5
Cagliari 4
Monterenzio 4
Bremen 3
Dong Ket 3
Irvine 3
Izmir 3
Norwalk 3
Ottawa 3
San Diego 3
Vicenza 3
London 2
Melbourne 2
Nanchang 2
Pozzuoli 2
Shenyang 2
Toronto 2
Tucson 2
Turin 2
Zhengzhou 2
Almaty 1
Atlanta 1
Balasore 1
Baltimore 1
Bungarribee 1
Chengdu 1
Chiswick 1
Dublin 1
Durham 1
Falls Church 1
Ferrara di Monte Baldo 1
Florence 1
Frankfurt am Main 1
Helsinki 1
Jiaxing 1
Lappeenranta 1
Los Angeles 1
Mountain View 1
New Bedfont 1
Osimo 1
Pamplona 1
Philadelphia 1
Piscataway 1
Redwood City 1
Taipei 1
Taiyuan 1
Taoyuan District 1
Tokyo 1
Washington 1
Zurich 1
Totale 684
Nome #
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 153
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 134
NOP receptor ligands and Parkinson’s disease 91
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 88
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 55
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 54
Therapeutic potential of RGS4 blockade in movement disorders 52
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 51
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia 49
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 48
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 38
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia 34
Totale 847
Categoria #
all - tutte 6.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 573
Totale 6.950


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202095 0 0 0 0 0 15 13 15 20 9 16 7
2020/2021167 11 14 10 3 17 2 24 19 9 22 17 19
2021/202295 2 2 4 2 2 14 8 14 6 7 11 23
2022/2023171 14 26 11 22 27 24 6 5 19 0 11 6
2023/202493 8 4 4 6 8 13 4 11 2 5 4 24
2024/2025150 5 9 37 5 27 67 0 0 0 0 0 0
Totale 847